Skip to content
Screener

United Therapeutics UTHR Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$783.3MMiss by $21.3M
EPS$7.27Beat by $0.41
Revenue estimate$804.6M
EPS estimate$6.86
“We believe that these submissions, accompanied by our planned filings later this year – an IND application for ralinepag DPI and an NDA for treprostinil SMI – may herald an opportunity for a quantum increase in our growth by the end of the decade. By next year, we expect potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH, two potentially transformative, multi-billion-dollar catalysts that could significantly enhance our growth profile. We expect Tyvaso DPI will then follow Nebulized Tyvaso's wake into IPF and then PPF. Moreover, our organ manufacturing pipeline continues to advance rapidly with clinical trials ongoing or being planned for liver, kidney, heart, and lung products, and the launch later this year of two xeno-organ production facilities in Minnesota and Texas.”
Martine Rothblatt

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q2 2026

Income statement

See full
Revenue$783.3M-1.9%
Gross profit$683.8M-3.8%
Operating income$330.8M-9.2%
Net income$333.0M+7.6%
EPS (diluted)$7.27+13.4%

Balance sheet

See full
Cash & equivalents$1.8B+13.2%
Total equity$6.4B-10.8%
Total assets$7.2B-8.7%

Cash flow

See full
Operating cash flow$313.6M+63.6%
CapEx$108.0M+73.6%
Free cash flow$205.6M+58.8%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$21.46B+17.1%
P/E16.4×+1.6×
P/S6.8×+0.8×

Profitability

See full
Gross margin86.1%-2.8pp
Operating margin44.4%-2.6pp
Net margin41.6%+1.2pp
FCF margin34.6%-0.1pp

Returns & leverage

See full
Return on equity19.3%0.0pp
Current ratio5.7×-1.5×

Segments

By product

See full
Tyvaso DPI$326.6M+3.6%
Remodulin$126.3M-6.2%
Nebulized Tyvaso$126.0M-18.4%
Orenitram$125.7M+1.5%
Unituxin$65.2M+11.6%

FAQ

When did United Therapeutics report Q2 2026 earnings?
United Therapeutics (UTHR) reported Q2 2026 earnings on August 5, 2026 before market open.
What were United Therapeutics's Q2 2026 revenue and EPS?
United Therapeutics reported revenue of $783.3M and eps of $7.27 for Q2 2026.
Did United Therapeutics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $804.6M by $21.3M. EPS beat the consensus estimate of $6.86 by $0.41.
How did United Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.9% from $798.6M a year earlier and eps grew 13.4% from $6.41.
Where can I find United Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001082554-26-000028) and the 10-Q periodic report (0001082554-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.